10X Genomics, Inc. (TXG)

NASDAQ: TXG · IEX Real-Time Price · USD
28.33
-0.15 (-0.53%)
At close: Oct 3, 2022 4:00 PM
28.68
+0.35 (1.24%)
After-hours: Oct 3, 2022 4:31 PM EDT
-0.53%
Market Cap 3.23B
Revenue (ttm) 497.93M
Net Income (ttm) -142.49M
Shares Out 113.91M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 619,344
Open 28.96
Previous Close 28.48
Day's Range 27.51 - 29.04
52-Week Range 27.51 - 187.85
Beta 1.70
Analysts Buy
Price Target 56.21 (+98.4%)
Earnings Date Nov 1, 2022

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Sep 12, 2019
CEO Serge Saxonov
Employees 1,239
Stock Exchange NASDAQ
Ticker Symbol TXG
Full Company Profile

Financial Performance

In 2021, 10X Genomics's revenue was $490.49 million, an increase of 64.13% compared to the previous year's $298.85 million. Losses were -$58.22 million, -89.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is 56.21, which is an increase of 98.41% from the latest price.

Price Target
$56.21
(98.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Should You Buy the Nasdaq's 10 Worst-Performing 2022 Stocks?

The best performer on this list has lost three-fourths of its value this year.

3 weeks ago - The Motley Fool

10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

PLEASANTON, Calif. , Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be part...

1 month ago - PRNewsWire

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

10x Genomics Reports Second Quarter 2022 Financial Results

PLEASANTON, Calif. , Aug. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022.

1 month ago - PRNewsWire

Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

PLEASANTON, Calif. , July 28, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be part...

2 months ago - PRNewsWire

10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade

Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's re...

2 months ago - Market Watch

10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation

10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company sees Ame...

2 months ago - Benzinga

10x Genomics stock falls as revenue forecast disappoints

Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics sha...

2 months ago - Market Watch

10x Genomics Names Jim Wilbur as Chief Commercial Officer

PLEASANTON, Calif. , July 14, 2022 /PRNewswire/ -- Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D.

2 months ago - PRNewsWire

10x Genomics Announces Preliminary Second Quarter 2022 Revenue

PLEASANTON, Calif. , July 14, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary rev...

2 months ago - PRNewsWire

3 Gene Sequencing Stocks With Potential to Gain in 2H22

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

Other symbols: PKITMO
2 months ago - Zacks Investment Research

7 Stocks to Buy That Could Make You a Millionaire

These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.

Other symbols: BRKRETSYMARPODDRHSEDG
3 months ago - InvestorPlace

10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting

Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissues Opens preorders for CytAssist, the company's first spatial instrument Shares new data on the company's Xe...

3 months ago - PRNewsWire

3 Cathie Wood Stocks That Could Deliver Monster Returns

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Other symbols: BEAMRXRX
3 months ago - The Motley Fool

My Favorite Biotech

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

Other symbols: AXSMDOCS
4 months ago - The Motley Fool

3 Unstoppable Stocks That Could Soar 58% to 97%, According to Wall Street

Analysts think the downturns for these stocks should only be temporary.

Other symbols: ISRGNVDA
4 months ago - The Motley Fool

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

10x Genomics Reports First Quarter 2022 Financial Results

Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022.

4 months ago - PRNewsWire

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

10x Genomics to Present at the BofA Securities 2022 Healthcare Conference

PLEASANTON, Calif. , April 26, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be par...

5 months ago - PRNewsWire

This Chart Is Why I'm Holding This Stock for the Next Decade

This biotech's products are a must-have for scientists.

5 months ago - The Motley Fool

10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium

Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis PLEASANTON, Calif. , April 14, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a l...

5 months ago - PRNewsWire

2 Top Biotech Stocks to Buy in April

These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.

Other symbols: GH
5 months ago - The Motley Fool

10x Genomics to Report First Quarter Financial Results on May 4, 2022

PLEASANTON, Calif. , April 7, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022.

5 months ago - PRNewsWire